Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 9/20 | 0.34 |
| ▸ | NOS3 | P29474 | 6/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20708485 | 0.74 | — | — | |
| SCHEMBL25297698 | 0.72 | IDO1 (0.33) | CYP1A2CYP2D6 | |
| SCHEMBL28719124 | 0.70 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL1404502 | 0.70 | MAPT (0.36) | MAPTKDM4EHTTRECQLALDH1A1 | |
| SCHEMBL7088058 | 0.70 | — | — | |
| SCHEMBL324748 | 0.70 | SMN1; SMN2 (0.32) | CYP1A2CYP2D6MAPTALDH1A1TSHR | |
| SCHEMBL5601100 | 0.67 | CALM1 (0.42) | CYP1A2ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL3629164 | 0.67 | IDO1 (0.48) | MAPTKDM4EHTTRECQLALDH1A1 | |
| SCHEMBL3082719 | 0.66 | MAPT (0.42) | CYP1A2MAPTKDM4EHTTALDH1A1 | |
| SCHEMBL5603177 | 0.65 | SMN1; SMN2 (0.35) | MAPTALDH1A1L3MBTL1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2212329-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORP (KR) | 2014-07-30 | — | — | EP | claimed |
| EP-1937669-B9 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-18 | — | — | EP | claimed |
| EP-1937669-B1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | claimed |
| US-7875644-B2 | tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas | MERCK PATENT GMBH (DE) | 2011-01-25 | — | — | US | claimed |
| CN-101827849-A | Novel compounds of reverse turn mimetics and the use thereof (1) | CHOONGWAE PHARMA CORP | 2010-09-08 | — | — | CN | claimed |
| EP-2212329-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | Choongwae Pharma Corporation (KR) | 2010-08-04 | — | — | EP | claimed |
| WO-2009051399-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | claimed |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-09 | — | — | US | claimed |
| CN-101243048-A | 1-acyldihydropyrazol derivatives | MERCK PATENT GMBH (DE) | 2008-08-13 | — | — | CN | claimed |
| EP-1937669-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-02 | — | — | EP | claimed |
| WO-2007027959-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | claimed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | claimed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| EP-1917248-B1 | 1-ACYLDIHYDROPYRAZOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2212329-B1 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORP (KR) | 2014-07-30 | — | — | EP | disclosed |
| WO-2007027959-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027780-A2 | BENZOPYRAN AND PYRANOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-01 | — | — | US | disclosed |
| WO-2007019933-A1 | 1-ACYLDIHYDROPYRAZOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MET, FLT3, ERBB3 | CYP1A2 437/4885CYP2D6 884/4885MAPT 4012/4885 |
| US-20070049556-A1 | NOVEL BENZOPYRAN DERIVATIVES AS POTASSIUM CHANNEL OPENERS | KCNJ2, KCNN1, KCNN3 | CYP1A2 874/4885CYP2D6 654/4885MAPT 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.